



# GREAT DEBATES

in Cardiometabolic Medicine

APRIL 8-10, 2022 | SCOTTSDALE, AZ

## CMHC SPRING 2022 **CONFERENCE GUIDE**



# TABLE OF CONTENTS

Welcome Letter	3
Hours of Operation	4
Schedule-at-a-Glance	8 - 12
Expert Speaker Line-Up	16 - 17
Spring 2022 CMHC Accreditation	20 - 21
CME Symposia	22 - 31
Association & Media Partners	32 - 33
Professional Medical Education (Non-CME)	33
Exhibitor Listings	34 - 36

## SENIOR PLANNING COMMITTEE



### **Deepak L. Bhatt, MD, MPH**

Professor of Medicine  
Harvard Medical School  
Executive Director  
Interventional Cardiovascular Programs  
Brigham and Women's Hospital Heart and Vascular Center  
Boston, MA



### **Pamela B. Morris, MD**

Director, Seinsheimer Cardiovascular Health Program  
Co-Director, Women's Heart Care  
Medical University of South Carolina  
Charleston, SC



### **Pam R. Taub, MD, FACC, FASPC**

Professor of Medicine  
Director, Step Family Foundation Cardiac Rehabilitation and Wellness Center  
UC San Diego  
San Diego, CA



### **Keith C. Ferdinand, MD, FACC, FAHA**

Professor of Medicine  
Gerald S. Berenson Endowed Chair in Preventive Cardiology  
Tulane University School of Medicine  
New Orleans, LA

### **Clyde W. Yancy, MD, MSc**

Magerstadt Professor of Medicine  
Professor of Medical Social Sciences  
Chief, Div. of Cardiology, Northwestern Univ.  
Feinberg School of Medicine  
Assoc. Director, Bluhm Cardiovascular Institute  
Northwestern Memorial Hospital  
Chicago, IL

## CHAIRPERSONS



### **George L. Bakris, MD**

Professor of Medicine  
Director, Am Heart Assoc. Comprehensive Hypertension Center  
University of Chicago Medicine  
Chicago, IL



### **Christie M. Ballantyne, MD**

Professor of Medicine  
Professor, Molecular and Human Genetics  
Professor, Molecular Physiology and Biophysics  
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory  
Director, Center for Cardiometabolic Disease Prevention  
Co-Director, Lipid Metabolism and Atherosclerosis Clinic  
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research  
Chief of Cardiology  
Chief of Cardiovascular Research  
Baylor College of Medicine



### **Robert H. Eckel, MD**

Professor of Medicine, Emeritus  
University of Colorado Anschutz Medical Campus  
Aurora, CO



### **Anne L. Peters, MD**

Professor, Keck School of Medicine, University of Southern California  
Director, USC Clinical Diabetes Programs  
USC  
Los Angeles, CA

# WELCOME TO CMHC SPRING 2022

Valued Colleagues,

Welcome to the beautiful Westin Kierland Resort & Spa for another exciting gathering of the most influential minds in cardiometabolic health. We are pleased to be back in Arizona for the Spring 2022 Cardiometabolic Health Congress (CMHC): Great Debates in Cardiometabolic Medicine. We have been busy making sure this weekend is a relaxing yet enlightening experience for our faculty presenters and provider audience – we can't wait to commence!

The Spring 2022 CMHC conference agenda has been designed by our distinguished Cardiometabolic Health Congress (CMHC) Planning Committee with careful attention to the newest developments in cardiometabolic medicine, while being mindful of the medical and global communities at large. We recognize that the second year of the COVID-19 pandemic has revealed not just the fragilities and disparities in our health care industry, but also some of the resiliencies. Always looking forward to a day when cardiometabolic health will be wholly realized and embraced by multidisciplinary practitioners everywhere, CMHC is focusing the 2022 congress on both facing the disparities and celebrating the resiliencies.

This three-day agenda will expose learners to clinical concepts and strategies designed to inspire a synergistic and comprehensive approach to cardiometabolic health. Since we last met, there have been exciting developments, including in the treatment of heart failure, obesity, lipid management, and progress in many other therapeutic areas we can't wait to delve into with our devoted faculty at the helm.

We hope you enjoy your stay in Scottsdale, time spent with valued colleagues, and most of all the critical cardiometabolic insights you'll bring home. Our loyal and committed attendees are our greatest asset – please accept our sincere thanks for being the momentum that keeps pushing the cardiometabolic health movement forward. We appreciate your steadfast support and hope to see you later this month in Hollywood, FL for Connecting the Dots in Cardiometabolic Medicine, or in Boston, MA for the 17th Annual CMHC on October 19 - 22, 2022.

Yours in Continued Good Health,  
The CMHC Team

# HOURS OF OPERATION

## REGISTRATION HOURS



APRIL  
7

THURSDAY

4:00 pm - 6:00 pm



APRIL  
8

FRIDAY

6:30 am - 5:00 pm



APRIL  
9

SATURDAY

7:00 am - 4:00 pm



APRIL  
10

SUNDAY

7:00 am - 11:30 am



## MEETING Wi-Fi ACCESS

NETWORK:  
**CMHC SPRING**  
PASSWORD:  
**Lokelma1**

SPONSORED BY



## BREAK AND EXHIBIT HOURS

### FRIDAY, APRIL 8, 2022

11:45 am - 12:15 pm (Morning Break & Exhibits)

1:15 pm - 1:45 pm (Break & Exhibits)

3:45 pm - 4:00 pm (Afternoon Break & Exhibits)

5:30 pm - 6:30 pm (Opening Reception)

### SATURDAY, APRIL 9, 2022

10:35 am - 11:05 am (Morning Break & Exhibits)

12:10 pm - 12:25 pm (Mini-Break)

1:25 pm - 1:40 pm (Mini-Break)

2:45 pm - 3:15 pm (Afternoon Break & Exhibits)

5:00 pm - 6:00 pm (Happy Hour & Giveaways)

### SUNDAY, APRIL 10, 2022

10:05 am - 10:20 am (Mini-Break)





# WELCOME RECEPTION

---

Friday, April 8  
5:30 PM - 6:30 PM

# HAPPY HOUR & GIVEAWAYS

---

Saturday, April 9  
5:00 PM - 6:00 PM



## 1<sup>ST</sup> PRIZE

TUMI - Small Compact  
4 Wheeled Brief



## 2<sup>ND</sup> PRIZE

Apple Watch



## 3<sup>RD</sup> PRIZE

AirPods



## 4<sup>TH</sup> PRIZE

17<sup>th</sup> Annual Cardiometabolic  
Health Congress Pass

# Passport to Prizes

**SATURDAY  
APRIL 9**

5:00 PM – 6:00 PM

**EXHIBIT HALL** The prize drawing will take place at 5:45 pm.

## HOW THE GAME WORKS

As an attendee, you will receive a passport book with your registration materials onsite at the conference. To play:

**1**

Visit each booth listed on the passport.

**2**

Speak and engage with the exhibitor; take some time to view and learn from their demonstrations.

**3**

Receive a sticker from the exhibitor to add to their corresponding square on your passport.

**4**

Once you have filled ALL the squares on your passport, return your completed game card to the CMHC registration table and you will be qualified to participate in the Grand Prize Drawing.

Attendees must be present to qualify for the prize drawings.



**AMGEN**<sup>®</sup>



**CALROY**  
HEALTH SCIENCES



arterosil



AstraZeneca



**B  
A  
BAYER  
E  
R**



**cmp**  
PHARMA



**Corcept**  
THERAPEUTICS

**THANK YOU SPONSORS**

[www.cardiometabolicehealth.org](http://www.cardiometabolicehealth.org)

# SCHEDULE AT A GLANCE

## FRIDAY, APRIL 8, 2022

7:00 AM – 8:30 AM

### **CME Breakfast Symposium (Non-CME)**

Bridging the Frontiers of Care in Patients with Type 2 Diabetes and Chronic Kidney Disease: Interpreting the Data with Novel MR Antagonists to Improve Cardiorenal Outcomes

George L. Bakris, MD (Chair)

Rajiv Agarwal, MD

Katherine R. Tuttle, MD

*Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.*

### **Opening Remarks & SESSION I: CARDIO-RENAL**

8:30 AM

Chair Introduction  
George L. Bakris, MD

8:30 AM – 9:15 AM

Outcomes Trials in Chronic Kidney Disease

I. Improving Renal Outcomes with SGLT-2 Inhibitors and GLP-1 RAs: Data, Interpretations, and Future Outlook

Katherine R. Tuttle, MD

II. Challenging CKD Case & Expert Panel Discussion

Katherine R. Tuttle, MD; Rajiv Agarwal, MD; George L. Bakris, MD

9:15 AM – 9:30 AM

Mini-break

9:30 AM – 11:00 AM

Outcomes Trials in Heart Failure

I. SGLT-2is and ARNI Across the HF Spectrum

Alanna A. Morris, MD

II. New and Emerging Treatment Targets in Heart Failure

Ileana L. Piña, MD

III. ATTR-CM in African Americans: Advances in Diagnosis and Treatment to Help Reduce Disparities and Improve Outcomes

*This session is supported in part by Alnylam Pharmaceuticals, Inc.*

Keith C. Ferdinand, MD

IV. HF Challenging Case & Expert Panel Discussion

Keith C. Ferdinand, MD; Alanna A. Morris, MD; Ileana L. Piña, MD; George L. Bakris, MD

11:00 AM – 11:45 AM

Emerging Developments in Hypertension

I. Emerging Treatments for Hypertension

Keith C. Ferdinand, MD

II. Resistant Hypertension: Old and New

Debbie Cohen, MD

III. Expert Panel Discussion & Audience Q & A

Keith C. Ferdinand, MD; Debbie Cohen, MD; George L. Bakris, MD

11:45 AM – 12:15 PM

Morning Break & Exhibits

# FRIDAY, APRIL 8, 2022

12:15 PM – 1:15 PM **PME Lunch Symposium**  
A Treatment Option for Patients With HFrEF Following a Worsening HF Event  
Matthew J. Budoff, MD  
*Sponsored by Merck Sharp and Dohme Corp.*

1:15 PM – 1:45 PM Break & Exhibits

1:45 PM – 2:30 PM **Keynote Address**  
Cardiometabolic Centers of Excellence – a Novel Care Delivery Model to Improve Quality and Outcomes in Cardiometabolic Disease  
Mikhail N. Kosiborod, MD

## SESSION II: DIABETES MANAGEMENT

2:30 PM Chair Introduction  
Anne L. Peters, MD

2:30 PM – 2:50 PM Prediabetes: Screening, Diagnosis, and Management  
Leigh Perreault, MD

2:50 PM – 3:25 PM Continuous Glucose Monitoring: Going Beyond HbA1c to Optimize and Individualize the Management of Type 2 Diabetes  
Viral Shah, MD  
*This session is supported by Abbott Diabetes.*

3:25 PM – 3:45 PM Dual GLP-1/GIP Agonists: Are They the Next Big Thing in Diabetes Treatment?  
Athena Philis-Tsimikas, MD

3:45 PM – 4:00 PM Afternoon Break & Exhibits

4:00 PM – 4:20 PM How Can We Converge the Gluco-centric and Cardio-Renal Risk Management in Diabetes Patients?  
Lawrence A. Leiter, MD

4:20 PM – 4:40 PM The Evolution of Insulin: A 2022 Update  
Grazia Aleppo, MD, FACE, FACP

4:40 PM – 5:00 PM Technology in Diabetes Beyond CGM  
Steven J. Russell MD, PhD

5:00 PM – 5:30 PM Expert Panel Discussion & Audience Q & A  
Moderator: Anne L. Peters, MD  
Panelists: Viral Shah, MD; Athena Philis-Tsimikas, MD; Lawrence A. Leiter MD; Grazia Aleppo, MD, FACE, FACP; Steven J. Russell MD, PhD

5:30 PM – 5:30 PM Closing Remarks  
Anne L. Peters, MD

5:30 PM – 6:30 PM Opening Reception

# SCHEDULE AT A GLANCE

## SATURDAY, APRIL 9, 2022

7:30 AM – 8:30 AM

### **CME Breakfast Symposium**

The Evolving Landscape of LDL-C Reduction in High-Risk Patients: Optimizing Combination Therapy to Reduce ASCVD Risk

Christie M. Ballantyne, MD (Chair)

Erin D. Michos, MD

Robert S. Rosenson, MD

Nihar R. Desai, MD

*Supported by an educational grant from Novartis Pharmaceuticals Corporation.*

### **SESSION III: OBESITY AND LIFESTYLE MEDICINE**

8:30 AM – 8:35 AM

Chair Introduction and Opening Remarks

Robert H. Eckel, MD

8:35 AM – 9:35 AM

Lifestyle Approaches to Target Obesity & Cardiometabolic Risk

I. Physical Activity

John Jakicic, PhD

II. Nutrition and Cardiometabolic Risk

Maya Vadiveloo, PhD, RD

III. Motivational Interviewing and Behavioral Strategies to Address Weight Management

Holly R. Wyatt, MD

9:35 AM – 9:55 AM

The Evolving Landscape of NAFLD and NASH

Kenneth Cusi, MD

9:55 AM – 10:35 AM

To Be Resolved: Which Approach is Better for Weight Loss?

I. Medical Management

Holly R. Wyatt, MD

II. Metabolic Surgery

Donna H. Ryan, MD

III. Clinical Implications: Expert Discussions & Audience Q/A

Donna H. Ryan, MD; Holly R. Wyatt, MD; Robert H. Eckel, MD

10:35 AM – 11:05 AM

Morning Break & Exhibits

11:05 AM – 11:25 AM

Addressing Bias, Stigma & Racial Disparities in Obesity Care

Fatima C. Stanford, MD

11:25 AM – 12:05 PM

Challenging Cases & Expert Panel Discussion and Q&A

Moderator: Robert H. Eckel, MD

Panelists: John Jakicic, PhD; Maya Vadiveloo, PhD, RD; Holly R. Wyatt, MD;

Fatima C. Stanford, MD; Donna H. Ryan, MD

12:05 PM – 12:10 PM

Closing Remarks

Robert H. Eckel, MD



# SATURDAY, APRIL 9, 2022

12:10 PM – 12:25 PM Mini-break

12:25 PM – 1:25 PM **CME Lunch Symposium**  
Changing The Treatment Paradigm for LDL-C Lowering Post-MI: The Case for Early, 'High-Intensity Lipid Lowering Therapy' to Improve Outcomes  
Christie M. Ballantyne, MD (Chair)  
Pam R. Taub, MD  
Salim S. Virani, MD  
*This activity is supported by educational funding provided by Amgen.*

1:25 PM – 1:40 PM Mini-break

## SESSION IV: DYSLIPIDEMIA/ATHEROSCLEROSIS/THROMBOSIS

1:40 PM – 1:45 PM Chair Introduction  
Christie M. Ballantyne, MD

1:45 PM – 2:05 PM ASCVD Risk Assessment and Prevention: Where Do We Stand Now?  
Salim S. Virani, MD

2:05 PM – 2:25 PM LDL-C-Lowering Therapies: New Approaches to Address Old Challenges  
Pam R. Taub, MD, FACC, FASPC

2:25 PM – 2:45 PM Lp(a) and Cardiovascular Risk  
Michael J. Wilkinson, MD

2:45 PM – 3:15 PM Afternoon Break & Exhibits

3:15 PM – 3:35 PM What's the Scoop with Triglycerides and ASCVD Risk?  
Karol E. Watson, MD

3:35 PM – 3:55 PM The Spectrum of Familial Hypercholesterolemia  
Robert S. Rosenson, MD

3:55 PM – 4:15 PM Updates in Antithrombotic Therapy for the Cardiometabolic Patient  
Roxana Mehran, MD

4:15 PM – 5:00 PM Challenging Cases & Expert Panel Discussion and Q&A  
Moderator: Christie M. Ballantyne, MD  
Panelists: Robert H. Eckel, MD; Salim S. Virani, MD; Pam R. Taub, MD, FACC, FASPC; Karol E. Watson, MD; Robert S. Rosenson, MD; Michael J. Wilkinson, MD

5:00 PM Closing Remarks  
Christie M. Ballantyne, MD

5:00 PM – 6:00 PM Happy Hour and Giveaways

# SCHEDULE AT A GLANCE

SUNDAY, APRIL 10, 2022

## Great Debates in Cardiometabolic Medicine

7:30 AM – 8:00 AM Breakfast

8:00 AM – 8:05 AM Introduction and Opening Remarks  
Christie M. Ballantyne, MD

8:05 AM – 9:05 AM Do patients benefit from Omega-3 Fatty Acids for CVD Prevention?  
I. Yes  
Michael Miller, MD  
II. No  
Karol E. Watson, MD  
III. Expert Discussions & Audience Q & A  
Christie M. Ballantyne, MD (Moderator)

9:05 AM – 10:05 AM What is the Standard of Care for Heart Failure with Preserved Ejection Fraction (HFpEF)?  
I. SGLT-2 Inhibitors  
Mikhail N. Kosiborod, MD  
II. ARNI and Others  
Alanna A. Morris, MD  
III. Expert Discussions & Audience Q & A  
Ileana L Piña, MD (Moderator)

10:05 AM – 10:20 AM Mini-break

10:20 AM – 11:20 AM Drawing The Line Between Primary and Secondary Cardiovascular Prevention: Essential or Too Simplistic?  
I. Essential  
Salim S. Virani, MD  
II. Too Simplistic  
Pam R. Taub, MD, FACC, FASPC  
III. Expert Discussions & Audience Q & A  
Christie Ballantyne, MD (Moderator)

11:20 AM – 12:20 PM The Plate Debate: Which Approach is Better for the Management of Obesity and Cardiometabolic Risk?  
I. Plant-based diets  
Monica Aggarwal, MD  
II. Low-carb diets  
David Ludwig, MD  
III. It's more complex than that  
Holly R. Wyatt, MD  
IV. Expert Discussions & Audience Q & A  
Moderator: Robert H. Eckel, MD

12:20 PM – 12:30 PM Closing Remarks  
Christie Ballantyne, MD



EDUCATIONALLY  
PARTNERED WITH



# Connecting the Dots in Cardiometabolic Medicine:

Integrative Approaches to Improve Patient Care

**APRIL 29 – 30, 2022**

THE DIPLOMAT BEACH RESORT IN HOLLYWOOD, FL



The American Academy of Anti-Aging Medicine (A4M) and Cardiometabolic Health Congress (CMHC) have partnered to deliver a unique 2-day meeting that will explore the connections between cardiometabolic risk and the spectrum of integrative and evidence-based interventions to improve cardiometabolic health.

Leveraging the strengths of A4M, a leader in integrative health & wellness, and CMHC, a leader in comprehensive cardiometabolic disease education, this meeting will combine the forward-thinking of integrative medicine approaches with cutting edge advances and clinical trials. Utilizing thought-provoking and interactive discussions, multidisciplinary experts will cover advances in lifestyle, nutrition, genetics, and pharmacotherapy to prevent and address obesity, cardiovascular disease, hypertension, dyslipidemia, type 2 diabetes, and kidney disease.

The meeting will be chaired by renowned experts George Bakris, MD and Mark Houston, MD, and will provide ample opportunity for interacting with thought leaders, with the ultimate goal of helping you walk away with practical and comprehensive strategies to improve patient care.

## CONFERENCE CO-CHAIRS



**George L. Bakris**  
MD



**Mark C. Houston,**  
MD, MS, FACP, ABAARM

## CONFERENCE VENUE



DIPLOMAT  
BEACH  
RESORT  
HOLLYWOOD,  
CURIO COLLECTION BY HILTON


3555 S Ocean Dr,  
Hollywood, FL 33019  
Phone: (954) 602-6000

REGISTER NOW  
AND **SAVE \$100**  
Use code **CMHC100**





All modules are available online



# Foundations of Cardiometabolic Health Certification Course

EARN 60+ HOURS OF CREDIT

## Certified Cardiometabolic Health Professional (CCHP)

MODULE 1: Lifestyle Management

MODULE 2: Obesity Management

MODULE 3: Type 2 Diabetes

MODULE 4: Hypertension

MODULE 5: Lipid Management

MODULE 6: Cardiovascular Disease  
COMING MAY 2022!

MODULE 7: Chronic Kidney Disease

MODULE 8: Implementing Care Delivery

MODULE 9: Cardiometabolic Considerations  
in Racial and Ethnic Minorities

### ONSITE SPECIAL

REGISTER TODAY AND SAVE **\$500** USE CODE **Spring500**



# LIVE

# Women's Cardiometabolic Health and Wellness Retreat

SEPTEMBER 9-11, 2022  
Rancho Palos Verdes, CA



This masterclass, led by co-chairs Pam R. Taub, MD and Erin D. Michos, MD will explore the unique challenges in optimizing cardiometabolic health in women across the lifespan. Through interactive and engaging conversations and presentations, experts will address important differences in cardiometabolic risk factors, symptom presentation, prevention and treatment of cardiometabolic diseases in women, as well as important implications for patient care.

More than a conference, this meeting is a true wellness retreat. Hosted in the beautiful Terranea resort on the Southern California coast, it is designed to offer ample opportunities for relaxing and recharging. The agenda for the meeting will be designed to allow you time to explore the resort and the area, and we will incorporate several wellness activities as part of the program. Additionally, there will be plenty of opportunities to interact and learn from the experts in an intimate setting through several networking events. Do not miss the chance to attend this unique retreat and to learn from the experts!

## MASTERCLASS CHAIRS



**PAM R. TAUB**  
MD, FACC,  
FASPC



**ERIN D MICHOS**  
MD, MHS,  
FACC, FAHA,  
FASE, FASPC

## CONFERENCE VENUE



### TERRANEA RESORT

100 Terranea Way.  
Rancho Palos Verdes, CA  
90275

# REGISTER NOW AND **SAVE \$100**

Use code **CMHC100**



# DISTINGUISHED FACULTY



## Rajiv Agarwal, MD

Professor of Medicine  
Indiana University School of Medicine & VA Medical Center  
Indianapolis, IN



## Monica Aggarwal, MD, FACC

Adjunct Associate Professor, Division of Cardiology  
Chief Medical Officer, 4Roots Farm  
University of Florida  
Orlando, FL



## Grazia Aleppo, MD, FACE, FACP

Professor of Medicine  
Director, NM Diabetes Training and Education Program  
Feinberg School of Medicine  
Northwestern University  
Chicago, IL



## Debbie L. Cohen, MD

Director, Hypertension  
Director, Pheochromocytoma/Paranglioma  
Neuroendocrine Tumor Program  
Professor of Medicine at the Hospital of the University of  
Philadelphia  
Philadelphia, PA



## Kenneth Cusi, MD, FACP, FACE

Professor of Medicine  
Chair, Division of Endocrinology, Diabetes & Metabolism  
University of Florida  
Gainesville, FL



## Nihar R. Desai, MD, MPH

Associate Professor of Medicine  
Yale School of Medicine, Section of Cardiovascular  
Medicine  
New Haven, CT



## John M. Jakicic, PhD

Professor  
University of Kansas Medical Center  
Kansas City, MO



## Mikhail N. Kosiborod, MD

Co-director, Haverty Cardiometabolic Center of Excellence  
VP Research, Saint Luke's Health System  
Executive Director, Cardiometabolic Center Alliance, Inc.  
Professor of Medicine (Cardiology)- University of  
Missouri-Kansas City  
Kansas City, MO



## Lawrence A. Leiter, MD

Professor of Medicine  
University of Toronto  
Toronto, Canada



## David S. Ludwig, MD, PhD

Boston Children's Hospital, Harvard Medical School  
Boston, MA



## Roxana Mehran, MD

Mount Sinai Professor in Cardiovascular Clinical Research  
and Outcomes  
Director of Interventional Cardiovascular Research and  
Clinical Trials  
Icahn School of Medicine at Mount Sinai  
New York, NY



## Erin D. Michos, MD, MHS

Associate Professor of Medicine (Cardiology) and  
Epidemiology  
Director of Women's Cardiovascular Health  
Associate Director of Preventive Cardiology  
Johns Hopkins University School of Medicine  
Baltimore, MD



## Michael Miller, MD, FACC, FAHA

Chief of Medicine, Corporal Michael J Crescenzi VAMC,  
Philadelphia  
Vice Chair of Medicine, Hospital of the University of  
Pennsylvania  
Philadelphia, PA



## Alanna A. Morris, MD, MSc

Associate Professor of Medicine  
Director of Heart Failure Research  
Emory University School of Medicine  
Atlanta, GA



## Leigh Perreault, MD

Associate Professor of Medicine, Epidemiology and  
Biostatistics  
University of Colorado  
Aurora, CO



## Athena Philis-Tsimikas, MD

Corporate Vice President  
Scripps Whittier Diabetes Institute  
San Diego, CA



# DISTINGUISHED FACULTY



**Ileana L. Piña, MD, MPH**

Professor of Medicine, Wayne State University  
Clinical Professor of Medicine  
Central Michigan University  
Mount Pleasant, MI



**Robert S. Rosenson, MD**

Professor of Cardiology and Director of Metabolism and Lipids  
Icahn School of Medicine at Mount Sinai  
New York, NY



**Steven J. Russell, MD, PhD**

Associate Professor of Medicine  
Massachusetts General Hospital Diabetes Research Center  
Boston, MA



**Donna H. Ryan, MD**

Professor Emerita  
Interim Executive Director  
Pennington Biomedical Research Center  
New Orleans, LA



**Viral Shah, MD**

Associate Professor of Medicine & Pediatrics, Barbara Davis Center for Diabetes  
University of Colorado Anschutz Medical Campus  
Aurora, CO



**Fatima Cody Stanford, MD, MPH, MPA**

Obesity Medicine Physician-Scientist  
Equity Director, Massachusetts General Hospital Endocrine Division  
Director of Diversity, Nutrition Obesity Research Center, Harvard Medical School  
Boston, MA



**Katherine R. Tuttle, MD**

Executive Director for Research, Providence Health Care  
Professor of Medicine, University of Washington  
Co-Principal Investigator, Institute of Translational Health Sciences, University of Washington/Providence Health & Services  
Spokane, WA



**Maya Vadiveloo, PhD, RD**

Assistant Professor  
University of Rhode Island  
Kingston, RI



**Salim S. Virani, MD, PhD**

Associate Professor, Section of Cardiovascular Research  
Director, Cardiovascular Disease Fellowship Training Program  
Baylor College of Medicine  
Staff Cardiologist, Michael E. DeBakey Veterans Affairs Medical Center  
Investigator, Health Policy, Quality and Informatics Program  
Michael E. DeBakey Veterans Affairs Medical Center HSR&D Center for Innovations  
Houston, TX



**Karol E. Watson, MD, PhD**

Professor of Medicine/Cardiology  
Co-director, UCLA Program in Preventive Cardiology  
Director, UCLA Barbra Streisand Women's Heart Health Program  
UCLA  
Redondo Beach, CA



**Michael Wilkinson, MD, FACC**

Assistant Professor  
Division of Cardiovascular Medicine  
UC San Diego  
San Diego, CA



**Holly R. Wyatt, MD**

Professor  
University of Alabama Birmingham  
Birmingham, AL

---

## REMEMBERING

---

*Dr. Sarah Hallberg*



As you may know, CMHC faculty member Dr. Sarah Hallberg passed away on March 28, 2022. She was scheduled to be here this weekend to deliver what would have been an enlightening session on her topic of expertise: the effect of low-carb diets on insulin resistance, obesity, and type 2 diabetes.

Dr. Sarah, as she was lovingly called by her patients, was an internationally recognized leader in the nutritional management of type 2 diabetes and other obesity-related diseases. The Tedx talk she delivered at Purdue University in 2015 on this topic has been viewed more than 8 million times, is used widely by physicians to educate their diabetic patients about their diet, and has inspired thousands to modify their lifestyles, ultimately reducing or even eliminating their need for medications.

Dr. Hallberg's constant push to challenge the status quo and advocate for evidence-based health guidelines was one of the reasons she was admired by her colleagues and adored by her patients.

**The entire CMHC team extends our deepest condolences to Brad, her husband of 24 years, and their children Noah, Ava, and Luna.**



The Premier Destination for Cardiometabolic Innovation

# THE PRESENT AND FUTURE

## OF CARDIOMETABOLIC HEALTH: ADVANCES AND EXPERT PERSPECTIVES

OCTOBER 19-22, 2022 | BOSTON, MA



The Annual Cardiometabolic Health Congress is making its return back to Boston in 2022—and you're invited! Join the foremost leaders in cardiometabolic medicine for an actionable examination on the latest research and updates in the field.



1000+ Attendees



100+ Speakers



50+ Sponsors

## CMHC CHAIRPERSONS



George L. Bakris,  
MD

NEPHROLOGIST



Christie M. Ballantyne,  
MD

CARDIOLOGIST




Robert H. Eckel,  
MD

ENDOCRINOLOGIST



Anne L. Peters,  
MD

ENDOCRINOLOGIST



### HOTEL INFORMATION

#### BOSTON PARK PLAZA

50 Park Plaza, Boston, MA 02116  
Rm Rate: \$329  
Expires: 8-24-22

**REGISTER NOW  
AND SAVE \$200**

Use coupon code **Annual22**

# 2022 SPRING CMHC CME INFORMATION

## ACTIVITY TITLE

CMHC Spring 2022: Great Debates in Cardiometabolic Medicine

## ACTIVITY DATE

April 8-10, 2022 at The Westin Kierland Resort & Spa, Scottsdale, AZ

## EDUCATIONAL GRANT SUPPORT

CMHC Spring 2022: Great Debates in Cardiometabolic Medicine is supported in part by an independent and unrestricted educational grant from Merck Sharp & Dohme Corp.

## TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dietitians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

## PROGRAM OVERVIEW

The 2022 CMHC Spring meeting will highlight the latest updates in CKD, heart failure, hypertension, type 2 diabetes, dyslipidemia, lifestyle management, obesity, and cardiovascular health, as well as aim to translate this cutting-edge medical research into practical, clinical strategies for preventing, delaying, and managing cardio-renal-metabolic disorders.

## EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

- Discuss the interrelationships among cardiometabolic risk factors and their impact on the development of cardiometabolic diseases
- Review the latest evidence and guidelines for the prevention, screening, and treatment of the complex patient with cardiometabolic risk or cardiometabolic disease
- Outline strategies aimed at timely screening and prevention of cardiometabolic disease, including assessment of risk factors and biomarkers, and lifestyle modifications
- Select individualized treatment regimens for patients with cardiometabolic disease based on the efficacy and safety of current and new pharmacotherapies, patient comorbidities and preferences in order to optimize outcomes

- Summarize recent evidence for emerging therapies in order to stay current with the most recent updates in the cardiometabolic field

## FACULTY

Please refer to the Expert Speaker Line-Up section in the conference guide.

## PROGRAM AGENDA

Please refer to the Schedule-at-a-Glance section in the conference guide.

## JOINT PROVIDERSHIP STATEMENT



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

## PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 16.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 16.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

## PHARMACIST ACCREDITATION STATEMENT



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

## Credit Designation

Global Education Group designates this continuing education activity for 16.25 contact hour(s) (1.625 CEUs) of the Accreditation Council for Pharmacy Education. Please refer to this [link](#) for a list of Universal Activity Numbers.

*This is a knowledge-based activity.*

## DIETITIAN ACCREDITATION STATEMENT



Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 16.25 Continuing Professional Education units (CPEUs) for completion of this activities / materials. *CPE Provider #GE012*

## GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

## DISCLOSURES

Information on planner and faculty disclosure is available by following this [link](#).

## DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

## DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or

other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

## FEE INFORMATION & REFUND/CANCELLATION POLICY

There is a registration fee for participating and receiving CME/CE credit for this educational activity. Registration information can be found [online here](#).

## HOW TO REQUEST CE CREDIT

Learners may earn up to a maximum of 19.75 AMA/ACPE/ANCC/CDR credits for attending all General Sessions (earn up to 16.25 hours) and CME Satellite Symposia (earn up to 3.5 hours). For educational symposia support information, including accreditation, please review the CME Symposia section of the conference guide. Upon completing the activity evaluations, your certificates will be emailed to you.

The evaluation links will be accessible on Sunday, April 10. [Visit this information page to access the evaluation links](#). Once the links are posted, attendees will be notified via announcements throughout the day. Several email reminders will be sent post-meeting.

Please claim your CE credits by completing the evaluations by Monday, April 25, 2022.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions about the accreditation of this activity, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

For questions regarding the evaluation, please contact: [cmhc\\_eval@cardiometabolichealth.org](mailto:cmhc_eval@cardiometabolichealth.org)



# CME BREAKFAST SYMPOSIUM

## FRIDAY, APRIL 8, 2022

7:00 – 8:30 AM

### **Bridging the Frontiers of Care in Patients with Type 2 Diabetes and Chronic Kidney Disease: Interpreting the Data with Novel MR Antagonists to Improve Cardiorenal Outcomes**

Chair: George L. Bakris, MD

Presenters: Rajiv Agarwal, MD; Katherine R. Tuttle, MD



*This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.*

Recent advances in the understanding of CKD progression in patients with type 2 diabetes have opened up new avenues of treatment that can potentially address some of the challenges and decrease cardiorenal risk in these patients. Of note, novel non-steroidal mineralocorticoid receptor antagonists (MRAs) are important new agents in this setting and have been recently FDA approved. During this symposium, experts will discuss these recent advances and their potential application to patient care.

#### **TARGET AUDIENCE**

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dietitians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.




#### **George L. Bakris, MD (Chair)**

Professor of Medicine  
Director, ASH Comprehensive Hypertension Center  
University of Chicago Medicine  
Chicago, IL



#### **Rajiv Agarwal, MD**

Professor of Medicine  
Indiana University School of Medicine & VA Medical Center  
Indianapolis, IN



#### **Katherine R. Tuttle, MD**

Executive Director for Research, Providence Health Care  
Professor of Medicine, University of Washington  
Co-Principal Investigator, Institute of Translational Health Sciences,  
University of Washington/Providence Health & Services  
Spokane, WA



## LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Recognize the burden of comorbid CKD and T2DM as a major driver of cardiovascular and renal morbidity and mortality.
- Identify T2DM patients at risk for kidney disease or kidney disease progression based on recommended diagnostic practices.
- Summarize the efficacy, safety, and mechanisms of action of nonsteroidal MRAs and other emerging treatment options for DKD.
- Select tailored treatment regimens that reduce the risk of cardiorenal adverse events in T2DM patients with CKD.

## EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

### JOINT PROVIDERSHIP STATEMENT



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

### PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

### PHARMACIST ACCREDITATION STATEMENT



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

### Credit Designation

Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-077-L01-P)

*This is a knowledge-based activity.*

### DIETITIAN ACCREDITATION STATEMENT



Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5

Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

### GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

### DISCLOSURES

Information on planner and faculty disclosure is available by following this [link](#).

### METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact [cmhc\\_eval@cardiometabolichealth.org](mailto:cmhc_eval@cardiometabolichealth.org)

### DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

# CME GENERAL SESSION

**FRIDAY, APRIL 8, 2022**

10:10 – 10:30 AM

## **ATTR-CM in African Americans: Advances in Diagnosis and Treatment to Help Reduce Disparities and Improve Outcomes**

Presenter: Keith C. Ferdinand, MD



*This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.*

ATTR cardiac amyloidosis (ATTR-CM) is a complex disease that remains challenging to diagnose and treat, and disproportionately affects African American patients. Low awareness about the disease, and limited therapeutic options are significant barriers to optimal care, however, significant advances have been made in the development of novel targeted-therapeutics that may improve patient outcomes. This session is going to cover some of those advances in order to increase awareness about current gaps and disparities in ATTR-CM.

### **TARGET AUDIENCE**

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dietitians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.



**Keith C. Ferdinand, MD, FACC, FAHA**

Professor of Medicine  
Gerald S. Berenson Endowed Chair in Preventive Cardiology  
Tulane University School of Medicine  
New Orleans, LA

## LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Define the pathophysiology, prevalence, and types of ATTR-CM.
- Recognize the disproportionate burden of ATTR-CM in African Americans and the significance of Val122I mutation.
- List current and emerging screening and diagnostic approaches aimed to optimize the early identification of African American patients with ATTR-CM.
- Review the different options for the treatment of ATTR-CM, including new and emerging novel targeted agents.

## EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Alnylam Pharmaceuticals, Inc.

### JOINT PROVIDERSHIP STATEMENT



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

### PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 0.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

### PHARMACIST ACCREDITATION STATEMENT



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

### Credit Designation

Global Education Group designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-065-L01-P)

*This is a knowledge-based activity.*

### DIETITIAN ACCREDITATION STATEMENT



Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive

0.5 Continuing Professional Education units (CPEUs) for completion of this activities / materials. *CPE Provider #GE012*

### GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

### DISCLOSURES

Information on planner and faculty disclosure is available by following this [link](#).

### METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact [cmhc\\_eval@cardiometabolichealth.org](mailto:cmhc_eval@cardiometabolichealth.org)

### DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

# CME GENERAL SESSION

**FRIDAY, APRIL 8, 2022**

2:50 – 3:25 PM

## **Continuous Glucose Monitoring: Going Beyond HbA1c to Optimize and Individualize the Management of Type 2 Diabetes**

Presenter: Viral N. Shah, MD



*This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.*

Measuring HbA1c has been the method of choice to assess glucose control; however, it does not reflect potential glucose excursions leading to hypoglycemia or postprandial hyperglycemia, which increase the risk of long-term complications, as well as overall glycemic variability. Continuous glucose monitoring (CGM) technology can circumvent some of these issues in T2DM management by providing near real-time glucose concentrations derived from interstitial fluid; and studies with CGM have demonstrated its efficacy and safety in this setting. This session is going to overview the guidelines for the use of CGM in T2DM, as well as important data and clinical considerations.

### **TARGET AUDIENCE**

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dietitians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.



**Viral Shah, MD**

Associate Professor of Medicine & Pediatrics, Barbara Davis Center for Diabetes  
University of Colorado Anschutz Medical Campus  
Aurora, CO

## LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Summarize the guidelines and evidence for the appropriate use of CGM in patients with type 2 diabetes.
- Explain ambulatory blood glucose profile (AGP) data and other important CGM metrics in patients with type 2 diabetes.
- List new and emerging CGM technologies and their associated clinical features.
- Incorporate the use of CGM when appropriate to individualize therapy in patients with type 2 diabetes.

## EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Abbott Diabetes.

### JOINT PROVIDERSHIP STATEMENT



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

### PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 0.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

### PHARMACIST ACCREDITATION STATEMENT



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

### Credit Designation

Global Education Group designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-068-L01-P)

*This is a knowledge-based activity.*

### DIETITIAN ACCREDITATION STATEMENT



Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive

0.5 Continuing Professional Education units (CPEUs) for completion of this activities / materials. *CPE Provider #GE012*

### GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

### DISCLOSURES

Information on planner and faculty disclosure is available by following this [link](#).

### METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact [cmhc\\_eval@cardiometabolichealth.org](mailto:cmhc_eval@cardiometabolichealth.org)

### DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

# CME BREAKFAST SYMPOSIUM

**SATURDAY, APRIL 9, 2022**

7:30 – 8:30 AM

## **The Evolving Landscape of LDL-C Reduction in High-Risk Patients: Optimizing Combination Therapy to Reduce ASCVD Risk**

Chair: Christie M. Ballantyne, MD

Presenters: Erin D. Michos, MD; Robert S. Rosenson, MD; Nihar R. Desai, MD



*This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.*

Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps. During this symposium, experts will discuss the efficacy and safety of these new approaches, how they fit in with the current treatment options for LDL-C lowering, and application to patient care.

### **TARGET AUDIENCE**

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dietitians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.



### **Christie M. Ballantyne, MD**

Professor of Medicine  
Professor, Molecular and Human Genetics  
Professor, Molecular Physiology and Biophysics  
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory  
Director, Center for Cardiometabolic Disease Prevention  
Co-Director, Lipid Metabolism and Atherosclerosis Clinic  
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research  
Chief of Cardiology  
Chief of Cardiovascular Research  
Baylor College of Medicine  
Houston, TX



### **Erin D. Michos, MD, MHS**

Associate Professor of Medicine (Cardiology) and Epidemiology  
Director of Women's Cardiovascular Health  
Associate Director of Preventive Cardiology  
Johns Hopkins University School of Medicine  
Baltimore, MD



### **Robert S. Rosenson, MD**

Professor of Cardiology and Director of Metabolism and Lipids  
Icahn School of Medicine at Mount Sinai  
New York, NY



### **Nihar R. Desai, MD, MPH**

Associate Professor of Medicine  
Yale School of Medicine, Section of Cardiovascular Medicine  
New Haven, CT



## LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk.
- Interpret the data from across major trials and real-world studies with PCSK9 inhibitors and their implications for patient selection
- Review the new approaches with novel LDL-C lowering agents and their potential impact in ASCVD risk reduction
- Select individualized treatment strategies for hypercholesterolemic patients that prioritize the early initiation and intensification of therapy to reduce ASCVD risk.

## EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

### JOINT PROVIDERSHIP STATEMENT



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

### PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

### PHARMACIST ACCREDITATION STATEMENT



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

### Credit Designation

Global Education Group designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-078-L01-P)

*This is a knowledge-based activity.*

### DIETITIAN ACCREDITATION STATEMENT



Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1

Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

### GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

### DISCLOSURES

Information on planner and faculty disclosure is available by following this [link](#).

### METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact [cmhc\\_eval@cardiometabolichealth.org](mailto:cmhc_eval@cardiometabolichealth.org)

### DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to be used as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

# CME LUNCH SYMPOSIUM

## SATURDAY, APRIL 9, 2022

11:25 AM – 12:25 PM

### Changing The Treatment Paradigm for LDL-C Lowering Post-MI: The Case for Early, 'High-Intensity Lipid Lowering Therapy' to Improve Outcomes

Chair: Christie M. Ballantyne, MD

Presenters: Salim S. Virani, MD, PhD; Pam R. Taub, MD



*This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.*

Patients with a recent myocardial infarction (MI) are classified as very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events according to current guidelines, however, targeted LDL-C achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal. For example, recent numbers from the GOULD registry, have shown that <40% of patients with a prior MI were on optimal LLT at enrollment, and only 13.2% had lipid therapy intensified.

In turn, these gaps perpetuate the risk of future adverse events that patients with a recent MI will experience. Despite the intensive medical management following an MI, risk of a recurrent CV event is substantial and patients with a recent MI have significant loss of productivity the year after the event. Furthermore, this burden is more pronounced in very high-risk patients, including those

with a high burden of cardiometabolic comorbidities, compared to patients who are not very-high risk. During this symposium, experts will provide guidance on the clinical application of statin and non-statin therapies in this setting, as well as information about new and emerging studies that can further inform patient selection in order to optimize outcomes.

#### TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dietitians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.



#### Christie M. Ballantyne, MD

Professor of Medicine  
Professor, Molecular and Human Genetics  
Professor, Molecular Physiology and Biophysics  
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory  
Director, Center for Cardiometabolic Disease Prevention  
Co-Director, Lipid Metabolism and Atherosclerosis Clinic  
J. S. Abercrombie Chair - Atherosclerosis and Lipoprotein Research  
Chief of Cardiology  
Chief of Cardiovascular Research  
Baylor College of Medicine  
Houston, TX



#### Salim S. Virani, MD, PhD

Associate Professor, Section of Cardiovascular Research  
Director, Cardiovascular Disease Fellowship Training Program  
Baylor College of Medicine  
Staff Cardiologist, Michael E. DeBakey Veterans Affairs Medical Center  
Investigator, Health Policy, Quality and Informatics Program  
Michael E. DeBakey Veterans Affairs Medical Center HSR&D Center for Innovations  
Houston, TX



#### Pam R. Taub, MD, FACC, FASPC

Professor of Medicine  
Director, Step Family Foundation Cardiac Rehabilitation and Wellness Center  
UC San Diego  
San Diego, CA

## LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

- Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk.
- Interpret the data from across major trials and real-world studies with PCSK9 inhibitors and their implications for patient selection
- Review the new approaches with novel LDL-C lowering agents and their potential impact in ASCVD risk reduction
- Select individualized treatment strategies for hypercholesterolemic patients that prioritize the early initiation and intensification of therapy to reduce ASCVD risk.

## EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

### JOINT PROVIDERSHIP STATEMENT



This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

### PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

### PHARMACIST ACCREDITATION STATEMENT



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

### Credit Designation

Global Education Group designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-079-L01-P)  
*This is a knowledge-based activity.*

### DIETITIAN ACCREDITATION STATEMENT



Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1

Continuing Professional Education units (CPEUs) for completion of these activities / materials. CPE Provider #GE012

### GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

### DISCLOSURES

Information on planner and faculty disclosure is available by following this [link](#).

### METHOD OF PARTICIPATION & REQUEST FOR CREDIT

Please refer to the 2022 CMHC Spring Accreditation page of this conference guide (pages 20-21) for instructions on how to access the evaluation link to this activity.

For Pharmacists: Pharmacists have up to 50 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

For questions regarding the evaluation, please contact [cmhc\\_eval@cardiometabolichealth.org](mailto:cmhc_eval@cardiometabolichealth.org)

### DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.



The 2022 Cardiometabolic Health Congress gratefully acknowledges the following

## ASSOCIATION PARTNERS



## MEDIA PARTNERS

## PROFESSIONAL MEDICAL EDUCATION (NON-CME)

Round out your CMHC educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies.

### PME LUNCH SYMPOSIUM

## A Treatment Option for Patients With HFrEF Following a Worsening HF Event

FRIDAY, APRIL 8, 2022  
12:15 -1:15 pm | TRAILBLAZERS BALLROOM

Presenter: Matthew Budoff, MD

SPONSORED BY:



# EXHIBITORS

## EXHIBIT BREAK HOURS

### FRIDAY, APRIL 8, 2022

11:45 am – 12:15 pm Morning Break & Exhibits

1:15 pm – 1:45pm Break & Exhibits

3:45 pm – 4:00 pm Afternoon Break & Exhibits

5:30 pm – 6:30 pm Opening Reception

### SATURDAY, APRIL 9, 2022

10:35 am – 11:05 am Morning Break & Exhibits

2:45 pm – 3:15 pm Afternoon Break & Exhibits

5:00 pm – 6:00 pm Happy Hour & Giveaways



## Amgen



1 Amgen Way  
Thousand Oaks, California 85383  
(602) 334-6831  
mancheta@amgen.com  
<https://www.amgen.com/>

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. For more information, visit [www.amgen.com](http://www.amgen.com) and follow us on [www.twitter.com/amgen](http://www.twitter.com/amgen).

## AstraZeneca



1800 Concord Pike  
Wilmington, DE 19803  
[www.astrazeneca-us.com](http://www.astrazeneca-us.com)

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit [www.astrazeneca-us.com](http://www.astrazeneca-us.com) and follow us on Twitter @AstraZenecaUS.

## Bayer Corporation



100 Bayer Boulevard  
Whippany, NJ 07981  
USA  
Phone: +1 862 404 3000  
[www.bayer.us](http://www.bayer.us)

We are one of the fastest-growing global pharmaceutical companies in the world. Our aim is to discover and manufacture innovative medicines that will improve human health worldwide by diagnosing, preventing and treating diseases. In this way, we are addressing the growing requirements of patients, physicians, healthcare payers and regulatory agencies.

## Calroy Health Sciences



arterosil

14362 N Frank Lloyd Wright, Suite 1000  
Scottsdale, Arizona 85260  
(800) 609-6409  
support@arterosil.com  
<http://www.arterosil.com>

Calroy is dedicated to developing innovative natural solutions to optimize cardiovascular health. The endothelium and EGX are gaining recognition in the medical community as essential focuses for vascular health. Calroy created Arterosil, the only glycocalyx-regenerating product patented to stabilize and regress vulnerable plaque\*. Arterosil's efficacy has been studied more than any EGX supplement with human, animal, and in vitro studies. Arterosil was the first supplement to address the EGX, and has the longest research history.

## CMP Pharma



P.O. Box 147  
8026 US Highway 264A  
Farmville, North Carolina 27828  
(760) 522-5780  
joanne.bodnar@cmppharma.com  
<http://cmppharma.com>

At CMP Pharma, we address the critical needs of older and younger patient populations through the development and manufacturing of a portfolio of high value semi-solid and liquid products. Our products include leading high-quality branded and generic prescription products, as well as a variety of non-prescription pharmaceutical products, which we distribute to hospitals, long-term care facilities, and retail channels. We've manufactured high-quality pharmaceutical products at our Farmville, North Carolina facility since 1986.

## Corcept Therapeutics



149 Commonwealth Drive  
Menlo Park, California 94025  
(650) 327-3270  
info@corcept.com  
<http://www.corcept.com>

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. The company's first product, Korlym® (mifepristone) 300mg Tablets has been approved by the FDA for the control of hyperglycemia associated with Cushing's syndrome. [www.corcept.com](http://www.corcept.com)

## Merck Sharp and Dohme Corp.,



351 N. Sumneytown Pike  
North Wales, Pennsylvania 19454  
(908) 740-4000  
mediarelations@merck.com  
<https://www.merck.com/>

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

# Clinically proven to protect and restore the endothelial glycocalyx

## **NEW PATENT!** **Arterosil stabilizes and regresses vulnerable plaque\***


### What It Is

Arterosil® is a proprietary dietary supplement formulated with a rare seaweed that contains specialized polysaccharides clinically proven to support arterial and endothelial health.

### Who It's For

Arterosil® delivers powerful support to patients with:

- Cardiovascular Disease
- Arterial or Carotid Plaque
- Coronary Artery Disease
- Erectile Dysfunction
- Diabetic Neuropathy
- Hyperglycemia
- Raynaud's
- Angina
- Diabetes
- Hypertension
- Hypercholesterolemia
- Peripheral Artery Disease



Endothelial Glycocalyx

### How It Works

The special polysaccharides in Arterosil® help rebuild the endothelial glycocalyx—the slippery inner lining of every artery, vein, and capillary in the body. This supports endothelial health, protects and stabilizes plaque, may regress plaque, and enhances NO production.

"The amazing results that I've had in my practice: on average, we're seeing about a **52% reduction in total carotid plaque**, and that's in people that I've been working with for years and have had on every integrative intervention, and most of them with really stubborn and difficult to reverse plaque."

KRISTINE BURKE, MD

U.S. Patent No. 11,135,238

\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.



# GREAT DEBATES

in Cardiometabolic Medicine

APRIL 8-10, 2022 | SCOTTSDALE, AZ

## CMHC SPRING 2022 **CONFERENCE GUIDE**

